Home
    Disclaimer
    Metonitazene molecular structure

    Metonitazene Stats & Data

    Nitazene Metonitazine
    NPS DataHub
    MW382.46
    FormulaC21H26N4O3
    IUPACN,N-diethyl-2-[2-[(4-methoxyphenyl)methyl]-5-nitrobenzimidazol-1-yl]ethanamine
    SMILESCCN(CC)CCn1c(Cc2ccc(OC)cc2)nc2cc(ccc12)N(=O)=O
    InChIKeyHNGZTLMRQTVPBH-UHFFFAOYSA-N
    Opioids; 2021/7. Von Benzimidazol abgeleitete Verbindungen; 2022/7. Von Benzimidazol abgeleitete Verbindungen
    Chemical Class Opioid
    Psychoactive Class Depressant
    Half-Life Unknown; likely short-to-moderate; human pharmacokinetic data limited

    Effect Profile

    Curated + 2 Reports
    Opioid 7.6

    Strong euphoria, itching/nausea, and pain relief with moderate sedation

    Euphoria / Warmth×3
    10
    Analgesia×2
    8
    Sedation / Relaxation×1
    7
    Itching / Nausea×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown; likely short-to-moderate; human pharmacokinetic data limited
    Addiction Potential
    Very high. Like other potent opioids, metonitazene carries a significant risk of dependence and addiction, with rapid tolerance development and severe withdrawal symptoms.

    Cross-Tolerances

    Other opioids (e.g., fentanyl, morphine, heroin)
    70% ●○○

    Experience Report Analysis

    Erowid
    2 Reports
    2021–2021 Date Range
    1 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Harm Reduction

    drugs.wiki

    Potency estimates for metonitazene vary by source and matrix; drug checking data has described it as roughly fentanyl-strength in some periods and up to ~4× fentanyl in others, underscoring high uncertainty across batches. It has increasingly appeared as an adulterant in samples not expected to contain high‑potency opioids (e.g., counterfeit oxycodone/“Percocet”, hydromorphone, and even cocaine/other non‑opioids), so assume unknown powders or pressed pills may contain a nitazene. Nitazenes, including metonitazene, are frequently found with other depressants such as benzodiazepine‑related drugs and veterinary tranquilizers (xylazine, medetomidine), which dramatically increase the risk of life‑threatening respiratory depression. Naloxone reverses nitazene overdoses but multiple sequential doses are often required; continue to administer naloxone every 2–3 minutes until breathing improves and emergency help arrives. Because fentanyl test strips do not detect nitazenes, a negative FTS result does not rule them out; some jurisdictions now distribute nitazene‑specific strips, but availability and sensitivity vary. Due to sub‑milligram potency and uneven distribution in powders, never eyeball; if handling any powder, use an accurate milligram scale and volumetric dilution to reduce hot‑spot risk. Avoid using alone; ensure someone can monitor breathing, place the person in the recovery position if unresponsive, and call emergency services promptly at the first sign of overdose (slow/absent breathing, cyanosis, unresponsiveness). Avoid combining with any sedatives (alcohol, benzos, gabapentinoids) and beware that stimulants can mask overdose signs without reducing respiratory depression. Metonitazene’s half‑life in humans is not well-established; observe for re‑sedation (“re‑narcotization”) after naloxone and seek medical monitoring. Not clinically approved for medical use; first identified in the unregulated drug supply around 2021 and subsequently implicated in fatalities in multiple countries.

    ← Back to Metonitazene